Available evidence suggests that refugees and internally displaced persons (IDPs) in stable settings can sustain high levels of adherence and viral suppression.
Moral, legal, and public health principles and recent evidence strongly suggest that refugees and IDPs should have equitable access to HIV treatment and support.
Exclusion of refugees and IDPs from HIV National Strategic Plans suggests that they may not be included in future national funding proposals to major donors.
Levels of viral suppression among refugees and nationals documented in a stable refugee camp suggest that some settings require more intensive support for all population groups.
Detailed recommendations are provided for refugees and IDPs accessing antiretroviral therapy in stable settings.
Canadian Institutes of Health Research (Doctoral Research Award, Priority Announcement for HIV/AIDS), Parkes Foundation (PhD Grant Fund), London School of Hygiene & Tropical Medicine (Research Training Support Grant), United Nations High Commissioner for Refugees (UNHCR)